MedTrace Logo

Trial of IMO-8400 in Adult Patients With Dermatomyositis

NCT02612857 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.

Conditions

  • Dermatomyositis

Interventions

DRUG

IMO-8400 Dose Group 1

IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.

DRUG

IMO-8400 Dose Group 2

IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.

DRUG

Placebo

normal saline subcutaneous injections once a week for 24 weeks.

Sponsors & Collaborators

  • Idera Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Joanna Horobin, MD · Idera Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-05-16
Completion
2018-06-30

Countries

  • United States
  • Hungary
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612857 on ClinicalTrials.gov